---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-024512"
form_type: "8-K"
ticker: null
cik: "0001843762"
company_name: "EQRx, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T03:20:36.131342+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EQRx Q4 net loss $22.2M, full year $169.1M; cuts headcount 18% to ~300 employees

## Summary
- Net loss Q4 2022 $22.2M vs net income $1.2M in Q4 2021; full year net loss $169.1M vs $100.0M in 2021.
- Cash, cash equivalents and short-term investments $1.4B at Dec 31, 2022; runway into 2028.
- 2023 cash used in operations expected <$275M.
- Restructuring: 18% headcount reduction to ~300 employees by end of Q1 2023; expected annualized cash savings ~$18M; one-time costs ~$4M.
- Pipeline: MAAs for aumolertinib and sugemalimab accepted by MHRA and EMA; Phase 3 trial for lerociclib in endometrial cancer expected 1H 2023.

## SEC filing metadata
- accession: 0001104659-23-024512
- form_type: 8-K
- cik: 0001843762
- company_name: EQRx, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1843762/000110465923024512/0001104659-23-024512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1843762/000110465923024512/tm237658d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-024512
- JSON: https://secwatch.observer/filing/0001104659-23-024512.json
- Plain text: https://secwatch.observer/filing/0001104659-23-024512.txt

## Key facts
- Earnings Releases
  EQRx, Inc. reported the fourth quarter ended December 31, 2022 results: net income $22.2 million.
  - Period: the fourth quarter ended December 31, 2022
  - Net income: $22.2 million
  - Result: reported results
  source text: Net loss totaled $22.2 million for the fourth quarter of 2022, as compared to net income of $1.2 million for the same period in 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1843762/000110465923024512/0001104659-23-024512-index.htm
- Restructurings & Charges
  EQRx, Inc. announced a restructuring with charges of approximately $4.0 million (an 18% decrease in headcount by the end of the first quarter of 2023 to approximately 300 employees).
  - Type: restructuring
  - Charge: approximately $4.0 million
  - Headcount: an 18% decrease in headcount by the end of the first quarter of 2023 to approximately 300 employees
  source text: On February 19, 2023, the board of directors of EQRx approved a restructuring plan (the Plan) to further increase EQRx’s operational efficiencies and streamline expenses, including an 18% decrease in headcount by the end of the first quarter of 2023 to approximately 300 employees, resulting from a reduction in force as well as not filling positions following departures. These efforts are expected to result in approximately $18.0 million in annualized cash savings. One-time payments associated with the reduction in force are expected to be approximately $4.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1843762/000110465923024512/0001104659-23-024512-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.